Equities

Glenmark Life Sciences Ltd

Glenmark Life Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,099.25
  • Today's Change9.25 / 0.85%
  • Shares traded88.60k
  • 1 Year change+73.44%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3,0142,8385,122
Total Receivables, Net9,3209,1837,152
Total Inventory6,8116,2195,162
Prepaid expenses8.061.381.63
Other current assets, total6.98262208
Total current assets19,16018,50317,646
Property, plant & equipment, net8,9628,2426,763
Goodwill, net------
Intangibles, net149180104
Long term investments0.770.7756
Note receivable - long term123130
Other long term assets11082141
Total assets28,50427,02124,710
LIABILITIES
Accounts payable3,6874,2723,077
Accrued expenses28484421
Notes payable/short-term debt000
Current portion long-term debt/capital leases242317
Other current liabilities, total393587325
Total current liabilities4,3884,9653,840
Total long term debt14817112
Total debt17119429
Deferred income tax488424315
Minority interest------
Other liabilities, total15879--
Total liabilities5,1815,6394,167
SHAREHOLDERS EQUITY
Common stock245245245
Additional paid-in capital10,05010,05010,050
Retained earnings (accumulated deficit)13,02911,08710,249
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity23,32321,38220,543
Total liabilities & shareholders' equity28,50427,02124,710
Total common shares outstanding123123123
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.